Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Posted on September 15, 2023September 18, 2023 by KBD Admin
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics Posted on September 5, 2023September 6, 2023 by KBD Admin
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock Posted on August 15, 2023August 29, 2023 by KBD Admin
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis Posted on July 25, 2023September 7, 2023 by KBD Admin
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics Posted on July 17, 2023August 29, 2023 by KBD Admin
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Posted on July 13, 2023August 29, 2023 by KBD Admin
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing Posted on June 26, 2023August 29, 2023 by KBD Admin
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes Posted on May 25, 2023August 29, 2023 by KBD Admin
